Yushan Jiang

Dr. Yushan Jiang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Molecular Plant-Microbe Interactions®
Verified
Journal Article
Closed access
SASoichiro Asuke
Soichiro Asuke
AHAkiko Horie
Akiko Horie
KKKaori Komatsu
Kaori Komatsu
RMRyota Mori
Ryota Mori
TVTrinh Thi Phuong Vy
Trinh Thi Phuong Vy
YTYukio Tosa
Yukio Tosa
Pyricularia oryzae, a blast fungus of gramineous plants, is composed of various host genus–specific pathotypes. The avirulence of an Avena isolate on wheat is conditioned by PWT3 and PWT4. We isolated the third avirulence gene from the Avena isolate and designated it as PWT7. PWT7 was effective as an avirulence gene only at the seedling stage or on leaves. PWT7 homologs were widely distributed in a subpopulation of the Eleusine pathotype and the Lolium pathotype but completely absent in the Triticum pathotype (the wheat blast fungus). The PWT7 homolog found in the Eleusine pathotype was one of the five genes involved in its avirulence on wheat. A comparative analysis of distribution of PWT7 and the other two genes previously identified in the Eleusine pathotype suggested that, in the course of parasitic specialization toward the wheat blast fungus, a common ancestor of the Eleusine, Lolium, Avena, and Triticum pathotypes first lost PWT6, secondly PWT7, and, finally, the function of PWT3. PWT7 or its homologs were located on core chromosomes in Setaria and Eleusine isolates but on supernumerary chromosomes in Lolium and Avena isolates. This is an example of interchromosomal translocations of effector genes between core and supernumerary chromosomes. [ ] Copyright © 2023 The Author(s). This is an open access article distributed under the CC BY-NC-ND 4.0 International license .

2 November 2022 in Journal of Infection
Verified
Journal Article
Closed access
MLMengjun Li
Mengjun Li
YWYuelin Wang
Yuelin Wang
CLChaohui Li
Chaohui Li
RXRui Xu
Rui Xu
JCJiayin Chen
Jiayin Chen
CSChenguang Shen
Chenguang Shen

28 July 2023 in Journal of Medical Virology
Verified
Journal Article
Closed access
YJYushan Jiang
Yushan Jiang
ZRZuning Ren
Zuning Ren
YYYang Yang
Yang Yang
JCJiayin Chen
Jiayin Chen
WZWei Zhao
Wei Zhao
CSChenguang Shen
Chenguang Shen

3 June 2022 in Journal of Medical Virology
Verified
Journal Article
Closed access
YJYushan Jiang
Yushan Jiang
HZHuan Zhang
Huan Zhang
JYJianhai Yu
Jianhai Yu
DHDong Huang
Dong Huang
LZLinlin Zhai
Linlin Zhai
CSChenguang Shen
Chenguang Shen

28 February 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
JWJiayang Wang
Jiayang Wang
QQQi Qian
Qi Qian
YJYushan Jiang
Yushan Jiang
ZLZuxin Liang
Zuxin Liang
YPYun Peng
Yun Peng
CSChenguang Shen
Chenguang Shen
Background/Objectives: COVID-19, caused by SARS-CoV-2, has emerged as a global pandemic since its outbreak in 2019. As an increasing number of variants have emerged, especially concerning variants such as Omicron BA.1, BA.2, XBB.1, EG.5, which can escape the immune system and cause repeated infections, they have exerted significant pressure on monoclonal antibodies and the treatment approaches for COVID-19. Broad spectrum antiviral medication was urgently needed. In this study, we developed several bispecific antibodies based on the IgG-scFv format and one trispecific antibody containing Fab fragments with different anti-virus mechanisms studied previously. The Fab fragments are from h11B11, S2P6, and S309 respectively. Method: all recombinant antibodies were expressed by HEK 293. The pseudoviruses’ neutralization assay and the virus challenge to BALB/c mice were deployed to assess the efficiency of recombinant antibodies in vitro and in vivo. Results: the bispecific antibodies exhibited a favorable pseudoviruses neutralization activity, with IC50 values ranging from 8 to 591 ng/mL. The trispecific antibody performed even better, with IC50 values ranging from 5 to 27 ng/mL. Furthermore, the virus challenge to mice confirmed that the bispecific antibodies, including the trispecific antibody, had decent therapeutic efficacy. Conclusions: our study provided several supplements to the therapeutic measures of COVID-19 based on multispecific antibodies, supporting the great potential of the multispecific antibodies strategy in dealing with emerging pathogens.

23 December 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
JLJinhu Liang
Jinhu Liang
LZLinlin Zhai
Linlin Zhai
ZLZuxin Liang
Zuxin Liang
WGwang guosong
wang guosong
YJYushan Jiang
Yushan Jiang
FWFuxiang Wang
Fuxiang Wang
Multitudinous broadly neutralizing antibodies (bNAbs) against HIV-1 have been developed as novel antiviral prophylactic and therapeutic agents. Combinations of bNAbs are generally even more effective than when they are applied individually, showing excellent neutralization coverage and limiting the emergence of escape mutants. In this study, we investigated the design and characterization of three trispecific antibodies that allow a single molecule to interact with independent HIV-1 envelope determinants—(1) the host receptor CD4, (2) the host co-receptor CCR5 and (3) distinct domains in the envelope glycoprotein of HIV-1—using an ELISA, an HIV-1 pseudovirus neutralization assay and in vivo antiviral experiments in humanized mice. We found that trispecific bNAbs and monovalent ones all had satisfactory binding activities against the corresponding antigens in the ELISA, exhibited higher potency and breadth than any previously described single bnAb in the HIV-1 pseudovirus neutralization assay and showed an excellent antiviral effect in vivo. The trispecific antibodies simultaneously recognize the host receptor CD4, host co-receptor CCR5 and HIV-1 envelope glycoprotein, which could mean they have promise as prophylactic and therapeutic agents against HIV-1.